FDA Provides Notice on Agendia's Ongoing MammaPrint Recall

The FDA's April 21 notice said that over a period of about six months, approximately 15 percent of MammaPrint results over-reported the chance of metastasis risk as 29 percent risk of recurrence instead of 10 percent.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.